Onconetix, Inc. (ONCO)
Data as of , from SEC Form 4 filings.
See up to 3 months of ONCO. The 7-day demo opens the 1M and 3M ranges and puts ONCO on your watchlist.
Start 7-day demoLatest ONCO insider trades
About Onconetix, Inc. (ONCO)
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer, approved for sale in the European Union. Additionally, it is focused on marketing Proclarix in the U.S. as a lab-developed product. Onconetix operates in one segment: commercial. Geographically, the company generates maximum revenue from Switzerland and the rest from the United Kingdom.
- CINCINNATI, OH
- 2
- 2022
- Nasdaq
ONCO Form 4 activity by transaction type, last 90 days
No Form 4 activity for ONCO in the last 90 days.
ONCO insider transactions (Form 4)
168 Form 4 filings on record, the earliest from Jul 14, 2025, newest first.
| Traded | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| HRT FINANCIAL LP - 10% Owner | Open-market sale | Class A Shares | 49,710 | $0.69 | $34K | |
| HRT FINANCIAL LP - 10% Owner | Open-market sale | Class A Shares | 53,867 | $0.73 | $39K | |
| HRT FINANCIAL LP - 10% Owner | Open-market purchase | Class A Shares | 34,636 | $0.73 | $25K | |
| HRT FINANCIAL LP - 10% Owner | Open-market sale | Class A Shares | 94,462 | $0.75 | $71K | |
| HRT FINANCIAL LP - 10% Owner | Open-market purchase | Class A Shares | 74,350 | $0.77 | $57K | |
| HRT FINANCIAL LP - 10% Owner | Open-market purchase | Class A Shares | 92,554 | $0.76 | $70K | |
| Andrew John Oakley - Director | Other | Common Stock | 20 | $0.00 | - | |
| Andrew John Oakley - Director | Grant or award | Common Stock | 618 | $0.00 | - | |
| Simon Tarsh - Director | Other | Common Stock | 39 | $0.00 | - | |
| Simon Tarsh - Director | Grant or award | Common Stock | 618 | $0.00 | - | |
| Thomas Meier - Director | Other | Common Stock | 39 | $0.00 | - | |
| Thomas Meier - Director | Grant or award | Common Stock | 618 | $0.00 | - | |
| Timothy R. Ramdeen - Director | Other | Common Stock | 39 | $0.00 | - | |
| Timothy R. Ramdeen - Director | Grant or award | Common Stock | 618 | $0.00 | - | |
| Altos Venture AG | Other | Common Stock | 241,514 | - | - | |
| Altos Venture AG | Other | Make-whole right (right to acquire) | 241,514 | - | - |
ONCO insider trading FAQ
What is the latest insider trade for ONCO?
Onconetix, Inc. (ONCO) has filed no insider reports in the last 90 days. The most recent on record is dated 22 April 2026. The full record for ONCO runs to 8 Form 4 filings, the earliest from 14 July 2025. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying ONCO stock?
No insider purchases of ONCO were filed in the last 90 days. 3 purchases are on record for this company.
How many insiders are selling ONCO stock?
No insider sales of ONCO were filed in the last 90 days. 3 sales are on record for this company.
Where can I see ONCO SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects ONCO Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
8The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - HRT FINANCIAL LP view on EDGAR
- - HRT FINANCIAL LP view on EDGAR
- - HRT FINANCIAL LP view on EDGAR
- - Andrew John Oakley view on EDGAR
- - Simon Tarsh view on EDGAR
- - Thomas Meier view on EDGAR
- - Timothy R. Ramdeen view on EDGAR
- - Altos Venture AG view on EDGAR
Related companies with recent insider activity
Learn more
- What the Form 4 transaction codes mean
- Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
- Insider activity in Health Care
- Where ONCO's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow ONCO with a 7-day demo
- ONCO on your watchlist
- Every ONCO Form 4 filing on record
- Up to 3 months of ONCO price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
